+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Free Fatty Acid Receptor 4"

Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Pipeline Review, H1 20 - Product Thumbnail Image

Free Fatty Acid Receptor 4 (G Protein Coupled Receptor 120 or G Protein Coupled Receptor 129 or G Protein Coupled Receptor GT01 or Omega 3 Fatty Acid Receptor 1 or G Protein Coupled Receptor PGR4 or GPR120 or GPR129 or FFAR4) - Pipeline Review, H1 20

  • Drug Pipelines
  • June 2018
  • 31 Pages
  • Global
From
  • 1 Results (Page 1 of 1)
Loading Indicator

The Free Fatty Acid Receptor 4 (FFAR4) market is a subset of the Endocrine and Metabolic Disorders Drugs market. FFAR4 is a G-protein coupled receptor that is involved in the regulation of glucose and lipid metabolism. It is a potential target for the development of novel therapeutics for metabolic diseases such as type 2 diabetes, obesity, and non-alcoholic fatty liver disease. FFAR4-targeting drugs are being developed by a number of pharmaceutical companies, including Novo Nordisk, Merck, Sanofi, and Eli Lilly. These companies are leveraging their expertise in drug discovery and development to create novel therapeutics that target FFAR4. Additionally, several biotechnology companies, such as Genfit and Metacrine, are also developing FFAR4-targeting drugs. Show Less Read more